Duke spin-out Aerie Pharmaceuticals has been given permission to begin testing its drug in Canada.
Aerie Pharmaceuticals, a spin-out of Duke University, has secured a “no objection letter” to trial its glaucoma treatment in Canada. The company expects some 1,300 patients to enrol in in the three phase 3 trials of Rhopressa, two of which are running in the US.
If the phase 3 trials of Rhopressa prove successful and the drug is approved, the spin-out intends to commercialise the drug throughout North America. It will do so by setting up its own dedicated sales…
